Abbott issues $20B multi-tranche notes; proceeds to fund Exact Sciences acquisition

ABBOTT LABORATORIES

Issued $20B in senior notes across 8 tranches: floating and fixed rates from 3.70% to 5.60%, maturities 2029-2066.
Net proceeds will fund the Exact Sciences acquisition, repay Exact Sciences debt, and for general corporate purposes.
Underwriters include Morgan Stanley, Barclays, BofA Securities, and J.P. Morgan Securities.
Closing expected on March 9, 2026, subject to customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ABBOTT LABORATORIES entered into Pricing Agreement with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC valued at $20,000,000,000 aggregate principal amount (effective 2026-02-23).

Action: entry
Agreement: underwriting
Counterparty: Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC
Value: $20,000,000,000 aggregate principal amount
Effective: 2026-02-23

Exact text from the filing

On February 23, 2026, Abbott Laboratories (“Abbott”) entered into a pricing agreement (the “Pricing Agreement”), dated February 23, 2026, by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein (the “Underwriters”), pursuant to which Abbott agreed to issue and sell $20,000,000,000 aggregate principal amount of senior notes

View on SEC.gov

336 material agreements filed in the last 30 days. Browse all material agreements →

ABBOTT LABORATORIES filing history →

Source: SEC EDGAR

accession 0001104659-26-020509

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.